版本:
中国

BRIEF-Morphosys, Galapagos start first-in-patient dosing of il-17c antibody MOR106

Sept 29 Galapagos NV :

* Morphosys and Galapagos start first-in-patient dosing of il-17c antibody MOR106 in atopic dermatitis

* Ongoing phase 1 study in healthy volunteers now advanced to investigate MOR106 in patients with atopic dermatitis

* Favorable safety results shown in healthy volunteers receiving single ascending doses (SAD) in the study to date Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐